modelN05AE05
Extends from Pharmacokinetic.Models.PK_1C_enteral.
Information
| name: | Lurasidone | |
| ATC code: | N05AE05 | route: | oral |
| compartments: | 1 | |
| dosage: | 40 | mg |
| volume of distribution: | 317 | L |
| clearance: | 390 | L/h |
| other parameters in model implementation | ||
Lurasidone is an atypical antipsychotic medication approved for the treatment of schizophrenia and bipolar depression in adults and adolescents. It acts primarily as an antagonist at dopamine D2, serotonin 5-HT2A, and 5-HT7 receptors. Lurasidone is currently approved and widely used.
Pharmacokinetics
Pharmacokinetic parameters for lurasidone in healthy adult subjects after oral administration. Data mainly reflect single-dose administration of 40 mg under fed conditions.
References
Hu, C, et al., & Jia, J (2017). Single- and Multiple-Dose Pharmacokinetics, Safety and Tolerability of Lurasidone in Healthy Chinese Subjects. Clinical drug investigation 37(9) 861–871. DOI:10.1007/s40261-017-0546-8 PUBMED:https://pubmed.ncbi.nlm.nih.gov/28695535
Rado, J, & Janicak, PG (2012). Pharmacological and clinical profile of recently approved second-generation antipsychotics: implications for treatment of schizophrenia in older patients. Drugs & aging 29(10) 783–791. DOI:10.1007/s40266-012-0009-0 PUBMED:https://pubmed.ncbi.nlm.nih.gov/23018584
McGrane, IR, et al., & Munjal, RC (2021). Roux-en-Y Gastric Bypass and Antipsychotic Therapeutic Drug Monitoring: Two Cases. Journal of pharmacy practice 34(3) 503–506. DOI:10.1177/0897190020905467 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32067562
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)